Multiple Myeloma

Early intensive therapy beneficial for primary resistant myeloma patients

Published in Cancer Vaccine Week, October 4th, 2004

Early intensive therapy is beneficial in patients with primary resistant myeloma.

"Clinical outcomes were evaluated in 89 consecutive patients with multiple myeloma that had not responded to dexamethasone-based primary therapy and who had received early intensive therapy supported by autologous stem cell transplantation.

"Results were compared with those of 45 comparable patients who refused or were unable to receive intensive treatment for socioeconomic reasons," scientists in the United States report.

"Following high-dose therapy," wrote R. Alexanian and coworkers, "the response rate was 69% including 16% with CR. Survival of 14...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Vaccine Week

Source: Cancer Vaccine Week (2004-10-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry